EXCLUSIVE Inside story of Blake Lively's disastrous attempt to copy Gwyneth Paltrow: Staff blow whistle on drugs, affairs and a bed IN THE OFFICE
Established in 2014, Preserve was meant to be Blake's answer to Gwyneth Paltrow 's , selling high-priced artisanal goods online. But it within a year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Reuters
15 minutes ago
- Reuters
Euro, US stock index futures climb after US-EU trade deal
NEW YORK, July 27 (Reuters) - Investors appeared to embrace news of a trade deal between the U.S. and European Union on Sunday that is expected to bring clarity for companies and some certainty to markets ahead of U.S. President Donald Trump's Friday tariffs deadline. The euro rose against the U.S. dollar and was last up 0.15% at $1.176. The currency also was up about 0.1% against the pound and 0.2% against the Japanese yen . U.S. stock index futures rose after resuming trading late Sunday, with S&P 500 e-minis last up 0.3% and Nasdaq futures up 0.4%. Nikkei futures also traded higher. Trump and European Commission President Ursula von der Leyen on Sunday announced the deal, which imposes a 15% import tariff on most European Union goods, half the threatened rate. The EU-US deal is similar to parts of the framework agreement the U.S. clinched with Japan last week, but it also leaves open questions, including tariff rates on spirits. "It's really in line with the Japan deal, and I assume investors will view it positively as they viewed the Japan deal," said Rick Meckler, partner at Cherry Lane Investments in New Vernon, New Jersey. "The reality is there will be higher tariffs, which may lead to more inflation, depending on how much of it is absorbed by the manufacturers and how much of it is passed on to consumers." Michael Brown, senior research strategist at Pepperstone in London, said: "For the euro, it removes that risk of a huge tariff and potentially getting towards trade embargo levels with the U.S." Optimism over easing trade tensions broadly helped push U.S. stocks to record highs last week and lifted European shares to their highest since early June. "It is odd to think that a late July week in the middle of the summer could prove to be the most pivotal of the year. It has already started with a key trade deal with a major partner," Michael O'Rourke, chief market strategist at JonesTrading in Stamford, Connecticut, wrote in a note following the news. Investors have been bracing for increased volatility heading into August 1, which the U.S. has set as a deadline for raising levies on a broad swath of trading partners. Trump's April 2 "Liberation Day" announcement of sweeping global tariffs sent stocks plunging in the immediate aftermath, due to spiking fears about a recession that have since faded. Holger Schmieding, chief economist at Berenberg Bank in London, said of the EU-U.S. announcement: "The crippling uncertainty is largely over, the deal is bearable for the EU. Modestly good news for equity markets, that probably priced in most of it beforehand. "But of course, the outcome is still bad relative to the situation that prevailed before Trump started his trade wars." The announcement came after Von der Leyen traveled to Scotland for talks with Trump to push a hard-fought deal over the line. Von der Leyen said the 15% tariff applied "across the board," including automobiles, semiconductors and pharmaceuticals. Trump said the deal also calls for $750 billion of EU purchases of U.S. energy in coming years and "hundreds of billions of dollars" of arms purchases. "We will need to see how long the sides stick to the deal," Eric Winograd, chief economist at investment management firm AllianceBernstein, said.
The Independent
an hour ago
- The Independent
WeightWatchers boss says ‘exciting work to do' amid impact of weight loss jabs
WeightWatchers was slower to adapt to the emergence of anti-obesity jabs than rivals, its boss has admitted, as the 62-year-old brand strives to catch up with rapidly evolving attitudes towards weight loss. Tara Comonte, chief executive of the US-based business, said it had a lot of work to do after going through a 'reset'. WeightWatchers recently announced it had emerged from bankruptcy after writing off a portion of the 1.15 billion US dollar (£860 million) debt on its balance sheet. It came as the business was competing with the emergence of GLP-1s – the scientific term for weight loss jabs, which work by reducing food cravings – and a new wave of apps and advice spreading on social media. Ms Comonte told the PA news agency that it 'wasn't as quick to medical weight loss solutions' as some other firms in the US, notably so-called 'telehealth' businesses that offer healthcare remotely. WeightWatchers, which runs some 20,000 workshops each month globally, is now 'at the beginning of the journey' towards forging a new place in the industry and meeting demand from current and future members, Ms Comonte said. 'This whole industry is going through somewhat of a reset and we have exciting work to do,' she told the PA news agency. 'This is a moment where, possibly more than ever before, people are talking about weight, and weight health… where people are seeking more education than ever before, and there are more voices than ever before.' Ms Comonte said the brand was known for 'trust and science' and it was important to harness that 'as there are more and more voices in the ecosystem'. WeightWatchers recently partnered with anti-obesity drugs provider CheqUp in the UK so patients taking the medication can access its 'companion' diet and lifestyle support app. It forms part of its efforts to muscle into the market by offering behavioural strategies and community-based support to people using or coming off the medication. 'There's no 'us and them' anymore,' Ms Comonte told PA, hitting back at weight loss jabs often being pitted as rivals to its model. Dr Kim Boyde, WeightWatchers' newly appointed chief medical officer, said not all its members will want or need weight loss medication – but stressed that it was 'imperative' the programme offers it to those that might benefit. Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs. Health officials have suggested that they can help to turn the tide on obesity, but have stressed they are not a silver bullet and do come with side effects.
Daily Mail
an hour ago
- Daily Mail
Shareholder revolt over Wise plans to move listing to New York
Wise faces a shareholder revolt today over its plan to move its primary listing to New York – after a falling out between its founders. Taavet Hinrikus – one of the fintech firm's founders – has urged investors to vote against the move on the grounds of concerns about shareholder rights that are tied up with the proposal. Wise's planned departure has been described as a 'hammer blow' to the City and will make it the latest in a string of UK-listed companies upping sticks for the US. Wise has said shareholders are 'overwhelmingly in favour' of the plans. A shareholder meeting to rubber stamp the move will be held today. Wise is led by boss Kristo Kaarmann, who founded it with Hinrikus, a fellow Estonian, in 2011. Hinrikus has since left the company but still owns a 5.1 per cent stake via his firm Skaala Investments.
